Clinical Trials Logo

Clinical Trial Summary

JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04469673
Study type Interventional
Source Shanghai Junshi Bioscience Co., Ltd.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date May 23, 2019
Completion date June 28, 2020

See also
  Status Clinical Trial Phase
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Not yet recruiting NCT02593487 - Effect of Rosuvastatin Therapy on HDL2 Level Phase 4
Active, not recruiting NCT02697422 - Veteran Peer Coaches Optimizing and Advancing Cardiac Health N/A
Recruiting NCT05912296 - A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022 Phase 1
Active, not recruiting NCT05432544 - Safety and Tolerability of SHR-1918 in Healthy Subjects Phase 1
Completed NCT03950752 - Effect of Consumption of Bagel Without Palm Oil on Postprandial Lipidemia N/A
Not yet recruiting NCT06229548 - A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 Phase 1
Completed NCT05532800 - The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia Phase 3
Completed NCT04781114 - The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia Phase 3
Active, not recruiting NCT04515927 - To Evaluate the Efficacy and Safety of JS002 in HoFH Patients Phase 2